Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

Researchers start first cancer operation room with navigator

A team of researchers from Gregorio Marañón Hospital, the company GMV and the Universidad Carlos III de Madrid (UC3M) have started the first cancer operation room with a navigator. This image-guided system will allow for increased intraoperative radiotherapy safety.

22 Dec 2013

CNAO Foundation places order for RayStation treatment planning system

RaySearch Laboratories AB has received an order for its RayStation® treatment planning system from CNAO Foundation (Centro Nazionale di Adroterapia Oncologica) in Pavia, Italy.

20 Dec 2013

RaySearch Laboratories, TomoTherapy terminate software licensing and development agreement

In 2007, RaySearch Laboratories AB and TomoTherapy Incorporated (now Accuray) entered into a software licensing and development agreement. Under the agreement, RaySearch developed a product named SharePlan, which was launched by TomoTherapy in 2009.

20 Dec 2013

New study aims to identify breast cancer patients most susceptible to post-treatment fatigue

Although the prevalence and impact of cancer-related fatigue has been well established, very little is known about its predictors, mechanisms for development, and persistence post-treatment. A new research study at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in partnership with UCLA, is aimed at identifying breast cancer patients most susceptible to post-treatment fatigue by measuring biological, behavioral and social risk factors.

19 Dec 2013

Elekta to launch MOSAIQ oncology information system throughout McLaren's cancer network

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ oncology information system throughout McLaren's cancer network.

From Elekta 18 Dec 2013

Elekta and McLaren Health Care to launch MOSAIQ oncology information system

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ® oncology information system throughout McLaren's cancer network.

From Elekta 18 Dec 2013

Pelvic radiation therapy to treat uterine cancer may increase risk of developing bladder cancer

Radiation therapy used to treat uterine cancer may increase a patient's risk of developing bladder cancer. That is the conclusion of a recent study published in BJU International.

18 Dec 2013

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.

17 Dec 2013

Experimental drug that targets macrophages decreases cancer's growth

An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer, scientists will report on Tuesday Dec. 17, at the American Society for Cell Biology annual meeting in New Orleans.

16 Dec 2013

Nucletron installs first Esteya electronic brachytherapy system for skin cancer treatment

The first Esteya electronic brachytherapy system in the United States has been installed at New York's Memorial Sloan-Kettering Cancer Center. Esteya by Nucletron, an Elekta company, is a new approach for skin cancer treatment that relies on a small, high dose rate (HDR) X-ray source to apply high precision radiotherapy directly to the cancer site.

From Elekta 16 Dec 2013

Experts develop innovative technologies to improve healthcare and border security

With a solemn ceremony organized on December 11, 2013 NCBJ concluded the 85.5 million PLN worth "AiD" R&D project co-financed by European Union. Project outcomes include 3 demonstrators of innovative medical devices (Coline 6, IntraLine, and InLine PN50) and 2 demonstrators of cargo scanners developed to improve security at European border crossing checkpoints (SWAN and CANIS).

13 Dec 2013

Over-use of staging procedures more prevalent in younger, early-stage breast cancer patients

More than one third of younger, early stage breast cancer patients undergo unnecessary imaging procedures - including position emission tomography (PET), computed tomography (CT), nuclear medicine bone scans (NMBS) and tumor markers (TM) -- at the time of staging and diagnosis, according to research from The University of Texas MD Anderson Cancer Center.

13 Dec 2013

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Researchers at the Roswell Park Cancer Institute Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers.

13 Dec 2013

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium.

12 Dec 2013

Surefire Medical enrolls patients in COSY clinical trial to investigate benefits of SIRT in liver metastasis

Surefire Medical, Inc. today announced that it has completed enrollment in the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial.

11 Dec 2013

Lawmakers close in on 'cease-fire' budget deal

Lawmakers are close to finding accord on a budget that would undo only a few parts of the government cuts known as "sequester." In addition, the proposed budget wouldn't lower the debt or change the costs involved with health care programs in addition to leaving other programs intact.

9 Dec 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

Low-income women less likely to receive breast cancer treatment

Women with interruptions in health insurance coverage or with low income levels had a significantly increased likelihood of failing to receive breast cancer care that is in concordance with recommended treatment guidelines, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.

9 Dec 2013

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection).

5 Dec 2013

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.

5 Dec 2013

Radiation Therapy News and Research

Further Reading

Researchers start first cancer operation room with navigator

CNAO Foundation places order for RayStation treatment planning system

RaySearch Laboratories, TomoTherapy terminate software licensing and development agreement

New study aims to identify breast cancer patients most susceptible to post-treatment fatigue

Elekta to launch MOSAIQ oncology information system throughout McLaren's cancer network

Elekta and McLaren Health Care to launch MOSAIQ oncology information system

Pelvic radiation therapy to treat uterine cancer may increase risk of developing bladder cancer

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Experimental drug that targets macrophages decreases cancer's growth

Nucletron installs first Esteya electronic brachytherapy system for skin cancer treatment

Experts develop innovative technologies to improve healthcare and border security

Over-use of staging procedures more prevalent in younger, early-stage breast cancer patients

RPCI enrolls patients in clinical trials of immunotherapy approaches for treating genitourinary cancers

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

Surefire Medical enrolls patients in COSY clinical trial to investigate benefits of SIRT in liver metastasis

Lawmakers close in on 'cease-fire' budget deal

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

Low-income women less likely to receive breast cancer treatment

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News